Table 3.

Adverse events.

Study	Vaccinated patients (n)	Doses provided per patient	Serious (Grade 3+) adverse events (n of events)	All adverse events (n of events)			Number of patients experiencing any AE
				Total (n)	Local complication (n)	Fever (n)
Oh (2020) Oh (2016)	31°	mean 7.8 (max 12)	None	93	93	0	NR
Bota (2018)†	5†	2 autologous cells, 3 allogeneic cells*	4	162	67	NR	NR
Schulze (2009)	25	6 (18 patients), 7 (1 patient), 11 (1 patient), 12 (1 patient), 3 (2 patients), 4 (1 patient), 5 (3 patients)	None	5	4	0	4
Peng (2006)	32	3	None	62	7	30	20
Uyl-de Groot (2005), Vermorken (1999)	128	4 (101 patients), 3 (1 patient), 1 (1 patient), unknown (25 patients)	None	NR	NR	NR	128
Peng (2005)	24	3 (24 patients), unspecified (6 patients)	None	72	72	0	24
Kuang (2004)	18	Unclear	None	NR	NR	0	18
Harris (2000)±	205	Unclear	None	NR	NR	NR	162
Galligioni (1996)	60	Unclear	None	NR	NR	NR	NR
Hoover (1993)	41	4 (1 patient), 3 (40 patients), 1 (1 patient)	None	NR	82	NR	41
Gray (1989, 1988)	129	NR	1	NR	NR	NR	NR
Adler (1987)	24	≤ 24 / Unclear	This study did not report on adverse events
Souter (1981)	34	1	This study did not report on adverse events
Embleton (1978), McIllmurray (1977)	8	1	None	NR	4	NR	NR

NR not reported.

°31 patients received vaccination; 20 of these patients were randomized to the vaccine group and 11 additional patients were placed in the vaccine group in a de-randomized fashion.

^†Bota (2018) was the only study to provide information on AEs for control; 8 serious AEs, 58 total AEs in control group.

*in the study by Bota et al. (2018) it was unclear how many cycles of the 2 autologous cell and 3 allogeneic cell vaccines were provided.

^±although only 150 patients were considered “analyzable” in the study by Harris (2000), 205 were vaccinated.